Septerna (NASDAQ:SEPN) Stock Price Up 6.1% – Time to Buy?

Septerna, Inc. (NASDAQ:SEPN) shares rose 6.1% on Friday . The stock traded as high as $32.84 and last traded at $33.48. 61,046 shares changed hands during trading, a decline of 83% from the average daily volume of 355,720 shares. The stock had previously closed at $31.56.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on SEPN shares. HC Wainwright restated a “buy” rating and issued a $40.00 price objective on shares of Septerna in a research report on Wednesday, July 1st. Guggenheim decreased their target price on shares of Septerna from $52.00 to $45.00 and set a “buy” rating on the stock in a report on Wednesday, July 1st. Truist Financial increased their target price on shares of Septerna from $35.00 to $43.00 and gave the stock a “buy” rating in a research note on Wednesday, July 1st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Septerna in a research note on Tuesday, April 21st. Finally, JPMorgan Chase & Co. raised their price target on shares of Septerna from $34.00 to $38.00 and gave the company an “overweight” rating in a report on Tuesday, March 24th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $45.89.

Septerna Trading Up 5.8%

The business’s fifty day moving average price is $32.15 and its 200-day moving average price is $28.11. The company has a market capitalization of $1.51 billion, a P/E ratio of -41.23 and a beta of 2.29.

Septerna (NASDAQ:SEPN) last released its earnings results on Monday, May 11th. The company reported ($0.19) EPS for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.23. Septerna had a negative return on equity of 12.72% and a negative net margin of 49.88%.The business had revenue of $26.52 million for the quarter, compared to analysts’ expectations of $16.98 million. As a group, equities research analysts forecast that Septerna, Inc. will post -1.59 EPS for the current year.

Insider Transactions at Septerna

In related news, insider Samira Shaikhly sold 11,798 shares of the business’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $30.06, for a total value of $354,647.88. Following the completion of the sale, the insider owned 793 shares in the company, valued at $23,837.58. The trade was a 93.70% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Daniel D. Long sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $35.51, for a total value of $532,650.00. Following the completion of the sale, the senior vice president directly owned 96,412 shares of the company’s stock, valued at approximately $3,423,590.12. This represents a 13.46% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 44,494 shares of company stock valued at $1,469,391 over the last quarter. Company insiders own 5.80% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Woodline Partners LP boosted its stake in shares of Septerna by 94.2% in the 1st quarter. Woodline Partners LP now owns 582,585 shares of the company’s stock valued at $3,373,000 after purchasing an additional 282,585 shares in the last quarter. Rhumbline Advisers raised its position in Septerna by 16.6% in the 1st quarter. Rhumbline Advisers now owns 23,318 shares of the company’s stock worth $135,000 after purchasing an additional 3,323 shares during the period. Geode Capital Management LLC raised its position in Septerna by 19.1% in the 2nd quarter. Geode Capital Management LLC now owns 487,956 shares of the company’s stock worth $5,158,000 after purchasing an additional 78,316 shares during the period. JPMorgan Chase & Co. lifted its stake in Septerna by 15.0% in the second quarter. JPMorgan Chase & Co. now owns 10,101 shares of the company’s stock worth $107,000 after purchasing an additional 1,315 shares during the last quarter. Finally, CW Advisors LLC bought a new stake in Septerna in the second quarter worth $133,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.